Open, uncontrolled, nonrandomized, 9-month, off-label use of bupropion to treat fatigue in a single patient with multiple sclerosis

Clinical Therapeutics

Volumn 32, Issue 12, 2010, Pages 2030-2034

  Siniscalchi, Antonio ^a   Gallelli, Luca ^b   Tolotta, Grazia Angela ^b   Loiacono, Daniela ^b   De Sarro, Giovambattista ^b  

^a Annunziata Hospital   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Amantadine; Bupropion; Fatigue; Multiple sclerosis

Indexed keywords

AMANTADINE; AMFEBUTAMONE;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CASE REPORT; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPWORTH SLEEPINESS SCALE; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FATIGUE SEVERITY SCALE; FEMALE; HUMAN; MULTIPLE SCLEROSIS; OFF LABEL DRUG USE; PITTSBURGH SLEEP QUALITY INDEX; RATING SCALE; TREATMENT DURATION;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; FATIGUE; FEMALE; HUMANS; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OFF-LABEL USE;

EID: 78649534298     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.10.012     Document Type: Article

References (28)

1. Fatigue and Multiple Sclerosis: Evidence-Based Management Strategies for Fatigue in Multiple Sclerosis 1998, Multiple Sclerosis Council for Clinical Practice Guidelines, Paralyzed Veterans of America, Washington, DC.
2. Freal JE, Kraft GH, Coryell JK Symptomatic fatigue in multiple sclerosis. Arch Phys Med Rehabil. 1984, 65:135-138.
3. Fisk JD, Pontefract A, Ritvo PG, et al. The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci. 1994, 21:9-14.
4. Kos D, Kerckhofs E, Nagels G, et al. Origin of fatigue in multiple sclerosis: Review of the literature. Neurorehabil Neural Repair. 2008, 22:91-100.
5. Murray TJ Amantadine therapy for fatigue in multiple sclerosis. Can J Neurol Sci. 1985, 12:251-254.
6. Weinshenker BG, Penman M, Bass B, et al. A double- blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology 1992, 42:1468-1471.
7. Polman CH, Bertelsmann FW, van Loenen AC, Koetsier JC 4-Aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. Arch Neurol. 1994, 51:292-296.
8. Rossini PM, Pasqualetti P, Pozzilli C, et al. Fatigue in progressive multiple sclerosis: Results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult Scler. 2001, 7:354-358.
9. Tomassini V, Pozzilli C, Onesti E, et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: Results of a pilot, randomised, double-blind, crossover trial. J Neurol Sci. 2004, 218:103-108.
10. Goodman AD, Brown TR, Cohen JA, et al. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology. 2008, 71:1134-1141. Fampridine MSF202 Study Group.
11. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD The Fatigue Severity Scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989, 46:1121-1123.
12. Krupp LB, Coyle PK, Doscher C, et al. Fatigue therapy in multiple sclerosis: Results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology. 1995, 45:1956-1961.
13. Buysse DJ, Reynolds CF, Monk TH, et al. The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res. 1989, 28:193-213.
14. Johns MW A new method for measuring daytime sleepiness: The Epworth Sleepiness Scale. Sleep. 1991, 14:540-545.
15. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961, 4:561-571.
16. Kale N, Agaoglu J, Tanik O Neuropsychiatric manifestations in multiple sclerosis: Correlation of fatigue and depression with disease progression. Neurol Res. 2010, 32:221-223.
17. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Can J Neurol Sci. 1987, 14:273-278. The Canadian MS Research Group.
18. Cohen RA, Fisher M Amantadine treatment of fatigue associated with multiple sclerosis. Arch Neurol. 1989, 46:676-680.
19. Goodnick PJ, Extein I Bupropion and fluoxetine in depressive subtypes. Ann Clin Psychiatry. 1989, 1:119-122.
20. Duffy JD, Campbell J Bupropion for the treatment of fatigue associated with multiple sclerosis. Psychosomatics. 1994, 35:170-171.
21. Breitbart W, Alici Y Pharmacologic treatment options for cancer-related fatigue: Current state of clinical research. Clin J Oncol Nurs. 2008, 12(Suppl 5):27-36.
22. Chauloff F Physical exercise and brain monoamines: A review. Acta Physiol Scand. 1989, 137:1-13.
23. Davis JM Nutrition, neurotransmitters and central nervous system fatigue. Nutrition in Sport. Osney Mead 2000, 173-188. Blackwell Science, Oxford, UK. R.J. Maughan (Ed.).
24. Leocani L, Colombo B, Magnani G, et al. Fatigue in multiple sclerosis is associated with abnormal cortical activation to voluntary movement-EEG evidence. Neuroimage. 2001, 13:1186-1192.
25. Rocca MA, Matthews PM, Caputo D, et al. Evidence for widespread movement-associated functional MRI changes in patients with PPMS. Neurology. 2002, 58:866-872.
26. Goldman-Rakic PS, Leranth C, Williams SM, et al. Dopamine synaptic complex with pyramidal neurons in primate cerebral cortex. Proc Natl Acad Sci U S A. 1989, 86:9015-9019.
27. Siniscalchi A, Calabrese P, Mercuri NB, Bernardi B Epileptiform discharge induced by 4-aminopyridine in magnesium-free medium in neo-cortical neurons: Physiological and pharmacological characterization. Neuroscience. 1997, 81:189-197.
28. Caruana DA, Chapman CA Dopaminergic suppression of synaptic transmission in the lateral entorhinal cortex. Neural Plast. 2008, 2008:203514.